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Background
Results
Bone Loss in KLHL3 Knock-In Mice  Characterized by a 
Pseudohypoaldosteronism Type II-like Phenotype is Mediated by Renal 
PTH Resistance
As expected, KLHL3R528H/+ mutants exhibited hyperkalemia, hypernatremia and renal calcium wasting. Furthermore, KLHL3R528H/+ mutants showed
elevated serum parathyroid hormone (PTH), increased bone resorption as demonstrated by elevated urinary collagen crosslinks excretion and increased
osteoclast numbers in femoral cancellous bone, and reduced distal femoral cancellous bone BMD and volume as evidenced by pQCT and µCT analysis.
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Taken together, our study provides a mechanistic explanation for the hypercalciuria and bone loss found
in PHAII patients: elevated WNK signaling increases NCC activity in KLHL3R528H/+ mice and blocks PTH‐
mediated TRPV5 activation, leading to renal PTH resistance with subsequent renal Ca wasting and a
counter‐regulatory PTH‐induced bone loss.
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Pseudohypoaldosteronism type II (PHAII) is a hereditary disease
characterized by hypertension, hypercalciuria and osteopenia. PHAII
is caused by mutations in with-no-lysine kinase 1 (WNK1), WNK4, or
the cullin RING ligase family members kelch-like 3 (KLHL3) or cullin 3
(CUL3). All mutations result in up-regulation of the WNK signalling
pathway which activates thiazide-sensitive Na-Cl cotransporters
(NCC) in renal distal tubules, leading to salt retention and
hypertension in PHAII. The mechanism underlying hypercalciuria in
PHAII is unknown. To better understand the mechanisms leading to
osteopenia in PHAII, we used KLHL3R528H/+ knock-in mice carrying
the same mutation as some PHAII patients.
WNK4
KLHL3
Ub
WNK4
WNK degradation
Normal
decresed degradation
PHAII
NCC
WNK4
KLHL3
Mutant
CUL3
WNK4
KLHL3
UbWNK4
NCC
*
*
1
R
el
at
iv
e 
Fl
uo
-4
flu
or
es
ce
nc
e 
in
te
ns
ity
1
R
el
at
iv
e 
Fl
uo
-4
flu
or
es
ce
nc
e 
in
te
ns
ity
1
R
el
at
iv
e 
Fl
uo
-4
flu
or
es
ce
nc
e 
in
te
ns
ity
• * p<0.05 vs. Veh
• # p<0.05 vs. PTH
• † p < 0.05 vs. ALD
